May 12Inflection Biosciences Announces Participation at Upcoming Industry Conferences Dublin, Ireland, May 12th, 2020 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, today announced that i...
Feb 19Inflection Biosciences Announces Appointment of Shaun McNulty, Ph.D., as Chief Scientific OfficerDublin, Ireland, February 19th, 2020 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, today announced t...
Feb 6Inflection Biosciences Announces Appointment of Murray Yule, M.D., Ph.D., as Chief Medical Officer(06 Feb 2020) Dublin, Ireland, February 6th, 2020 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, tod...
Jan 31Inflection Biosciences to Present at BIO CEO & Investor Conference 2020Dublin, Ireland, January 31, 2020 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, today announced tha...
Nov 26, 2019Inflection Biosciences Selected as Tech Tour Contest Finalist for 2019Dublin, Ireland, November 26, 2019 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, today announced th...
Oct 30, 2019Inflection Biosciences Announces Passing of Co-Founder and Board Member John ScanlanDublin, Ireland, October 30, 2019 – Inflection Biosciences Ltd today announced that John Scanlan, a co-founder and a member of its Board of Directors, passed...
Sep 9, 2019Inflection Biosciences Announces Pre-clinical Data to be Presented at IASLC 2019 World Conference onDublin, Ireland, September 9th, 2019 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, today announced ...
Aug 7, 2019Inflection Biosciences Announces Publication of Positive Data for PIM/PI3K/mTOR InhibitorDublin, Ireland, August 7, 2019 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, today announced the p...
Jul 18, 2019Inflection Biosciences and AUM Biosciences announce Global License Agreement for PIM/PI3K/mTOR Dublin, Ireland, 18 July 2019 – Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of cancer, and AUM Biosci...
Nov 28, 2018Inflection Biosciences Announces Pre-clinical Data to be Presented at 2018 AACR Targeting PI3K/mTOR Dublin, Ireland, November 28th, 2018 – Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced that new ...
